ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myeloid Leukemia
Myelodysplastic Syndromes
Lymphoid Leukemia
Lymphoma

Leukemia trials near Paris, Île-de-France, FRA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...

Active, not recruiting
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib
Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Paris, France and 43 other locations

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 4 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Paris, France and 56 other locations

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

Phase 1, Phase 2

Incyte
Incyte

Paris, France and 24 other locations

WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with acute myeloid leukemia (AML) who are in morphol...

Enrolling
Acute Myeloid Leukemia
Drug: Cyclophosphamide-Fludarabine (Cy/Flu)
Drug: oNKord®

Phase 1, Phase 2

Glycostem Therapeutics

Villejuif, France and 9 other locations

safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia...

Active, not recruiting
Chronic Myeloid Leukemia
Drug: Venetoclax

Phase 2

Groupe Francophone des Myelodysplasies

Paris, France and 23 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Azacitidine
Drug: IMGN632

Phase 1, Phase 2

AbbVie
AbbVie

Paris, France and 28 other locations

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia....

Enrolling
Leukemia, Lymphocytic, Acute
Leukemia, Myeloid, Acute
Drug: azoles
Drug: Gilteritinib

Phase 1, Phase 2

Sumitomo Pharma
Sumitomo Pharma

Paris, France and 103 other locations

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling
Myeloid Leukemia, Philadelphia Positive
Drug: Asciminib Adult formulation group
Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis
Novartis

Paris, France and 38 other locations

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Paris, France and 48 other locations

participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...

Enrolling
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase
Drug: TERN-701

Phase 1, Phase 2

Terns Pharmaceuticals

Paris, France and 53 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems